(Q43797374)

26 November 2017

title

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study (English)

1 reference

26 November 2017

1 reference

A T van Oosterom

1

1 reference

26 November 2017

I Judson

2

1 reference

26 November 2017

J Verweij

3

1 reference

26 November 2017

S Stroobants

4

1 reference

26 November 2017

E Donato di Paola

5

1 reference

26 November 2017

S Dimitrijevic

6

1 reference

26 November 2017

M Martens

7

1 reference

26 November 2017

A Webb

8

1 reference

26 November 2017

R Sciot

9

1 reference

26 November 2017

M Van Glabbeke

10

1 reference

26 November 2017

S Silberman

11

1 reference

26 November 2017

O S Nielsen

12

1 reference

26 November 2017

European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

13

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

358

1 reference

26 November 2017

issue

9291

1 reference

26 November 2017

page(s)

1421-1423

1 reference

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906535-7

7 January 2021

Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906535-7

7 January 2021

Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906535-7

7 January 2021

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906535-7

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906535-7

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906535-7

7 January 2021

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906535-7

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906535-7

7 January 2021

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906535-7

7 January 2021

10.1016/S0140-6736(01)06535-7

Identifiers

DOI

1 reference

release_dqfbinfvnjhwxk2pswmkxnlnia

26 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dqfbinfvnjhwxk2pswmkxnlnia

24 November 2022

mapped directly with Wikidata item

1 reference